This observational study characterized glycemic profiles and treatment patterns of a large cohort of pediatric and adolescent patients with T1D using the Omnipod® Insulin Management System (Insulet Corp., Acton, MA) with integrated BG meter (Abbott Diabetes Care Inc., Alameda, CA) and data management system (Glooko, Mountain View, CA). From January 2015 through September 2018, usage data from the pump system were uploaded to the data management system and matched via device serial number to a second database of self-reported demographic data and de-identified. BG and insulin data from ≥3 months of system use per patient were analyzed. Demographics, glycemic profiles and insulin use of pediatric and adolescent patients with T1D (n=9,914) stratified by age group <6 y (n=499), 6 to <12 y (n=3,560) and 12 to <18 y (n=5,855) are reported in the Table. Mean glucose was 192±32, 190±31 and 201±39 mg/dL and bolus frequency per day was 7.5±2.8, 6.4±2.2 and 5.3±2.1 in the <6 y, 6 to <12 y and 12 to <18 y groups, respectively. These real-world data from a large cohort of youth with T1D demonstrate that use of a tubeless insulin pump was associated with BG levels that compare favorably to large registries including the T1D Exchange. These data also highlight important management patterns including frequent bolusing with Omnipod® System use.

J.E. Layne: Employee; Self; Insulet Corporation. Y. Zheng: Employee; Self; Insulet Corporation. Stock/Shareholder; Self; Insulet Corporation. J. He: Employee; Self; Insulet Corporation. J. Jantz: Employee; Self; Insulet Corporation. Employee; Spouse/Partner; Insulet Corporation. E. Benjamin: Employee; Self; Insulet Corporation. T.T. Ly: Employee; Self; Insulet Corporation.


Insulet Corporation

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at